MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Supernus Pharmaceuticals EV/EBITDA Ratio 2011-2026 | SUPN
Annual EV/EBITDA Ratio Supernus Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.1 | 8.48 | 8.97 | 13.6 | 18 | 21.1 | 27.5 | 13.9 | -5.12 | -2.83 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.5 | -5.12 | 12.3 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioNTech SE
BNTX
|
4.1 | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M | Germany |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-249 | $ 3.54 | -20.81 % | $ 238 B | Britain |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-31.5 | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-1.31 | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
-39.4 | $ 748.25 | 0.25 % | $ 25 B |  Niderland |
 |
Завод ДИОД
DIOD
|
7.12 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-115 | - | - | - | Russia |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
29.4 | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
-0.476 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
2.8 | - | -13.85 % | $ 16.1 M | USA |
 |
AbbVie
ABBV
|
11.9 | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
-7.26 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
-0.158 | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
-1.96 | - | - | $ 2.91 B | USA |
 |
AbCellera Biologics
ABCL
|
9.24 | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.37 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
0.0336 | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Genmab A/S
GMAB
|
2.7 | $ 27.75 | 0.91 % | $ 17.6 B |  Danmark |
|
Cerevel Therapeutics Holdings
CERE
|
-19.7 | - | - | $ 7.29 B | USA |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 8.23 | -0.12 % | $ 6.83 B |  Spain |
 |
Akebia Therapeutics
AKBA
|
-2.4 | $ 1.32 | -4.35 % | $ 339 M | USA |